Statistics from Altmetric.com
“PRIMARY” NASH AND THE DYSMETABOLIC SYNDROME
Histopathological characteristics distinguish steatohepatitis from other causes of chronic liver injury. For years, the main cause of steatohepatitis was thought to be excessive consumption of alcohol. Increasingly, steatohepatitis is being diagnosed in individuals who deny alcohol abuse. Arbitrarily, “non-alcoholic” steatohepatitis (NASH) is subcategorised into “primary” and “secondary” NASH.1
Primary NASH refers to steatohepatitis that is associated with the dysmetabolic syndrome (that is, obesity, type 2 diabetes, dyslipidaemia).2 Primary NASH is thought to be the predominant form of NASH, afflicting at least as many individuals in the USA as chronic hepatitis C. Secondary NASH refers to steatohepatitis that accompanies other syndromes (for example, lipodystrophy) or that is caused by certain drugs (for example, amiodarone).3 Accumulating evidence suggests that common mechanisms may mediate the pathogenesis of alcohol induced steatohepatitis and primary NASH.4 Although unproven, it is likely that primary and secondary NASH also share common pathogenic mechanisms.
PATHOGENIC RELEVANCE OF NASH ASSOCIATED DISORDERS
Obesity, especially visceral adiposity, is a major risk factor for NASH in humans.5 Even if they do not have an elevated body mass index, patients with NASH are very likely to be insulin resistant.2 Basic research on fat cell (adipocyte) biology provides some clues about why obesity, insulin resistance, and NASH may be interrelated.
Obesity increases adipose tissue mass. It has long been known that adipose tissue is a source of free fatty acids that are delivered to the liver and a depot for triglycerides that are synthesised by hepatocytes and released into the blood. Only recently however has the neuroendocrine role of adipose tissue been appreciated. Fat produces hormones, such as leptin, resistin, and adiponectin, that regulate metabolism in other tissues, as well as fat itself. Fat is also a source of neurotransmitters, such as noradrenaline and angiotensin II. In addition, because adipocytes produce immunomodulatory cytokines, such as tumour necrosis factor (TNF)-α and interleukin (IL)-6, fat is a component of the immune system.6–8
Given the neuroendocrine and immunomodulatory functions of fat, it is not surprising that absolute increases in adipose tissue mass influence systemic energy homeostasis, intermediary metabolism, and immune function. The situation is further complicated by the likelihood that there are both qualitative and quantitative differences in the factors (aka, “adipokines”) that are produced by different fat depots. For example, visceral fat, which appears to be less “mature” than subcutaneous fat, produces more TNF-α and free fatty acids but less adiponectin than subcutaneous fat, which produces large amounts of leptin.7 Thus the ultimate consequences of obesity may differ depending on which fat depots predominate.
Visceral fat depots, TNF-α, hepatic insulin resistance, and fatty liver
Visceral adiposity in particular has been strongly associated with the dysmetabolic syndrome and NASH.9–12 Visceral fat promotes fatty liver disease by several mechanisms. Firstly, intra-abdominal fat provides an immediate source of free fatty acids that are delivered directly into the portal vein.11 In mice, situations that increase the delivery of free fatty acids to tissues, including the liver, induce localised insulin resistance.13 In addition, gene disruption studies in mice have proven that interference with insulin signalling in hepatocytes (that is, hepatocyte insulin resistance) activates fat synthesising enzymes in these cells and results in hepatic steatosis.14 Secondly, individuals with truncal obesity have extremely low levels of adiponectin and relatively high levels of TNF-α.15 TNF-α is known to activate intracellular signalling molecules, including stress related kinases such as Jun N-terminal kinase and inhibitor kappa beta kinase beta, that make cells resistant to the actions of insulin.13,16,17 Adiponectin antagonises both the production and activity of TNF-α.18–21 Therefore, TNF-α actions are potentiated when adiponectin is scarce.22 In addition, TNF-α itself inhibits adiponectin.23,24 Adiponectin acts directly on hepatocytes to inhibit fatty acid synthesis and uptake while stimulating fatty acid oxidation.25–27 Therefore, adiponectin itself also enhances hepatocyte sensitivity to insulin.28,29 The combination of low adiponectin and high TNF-α levels in the context of increased hepatic exposure to free fatty acids results in hepatic steatosis and severe hepatic insulin resistance.30–32 The importance of visceral fat in the pathogenesis of hepatic insulin resistance and steatosis has been demonstrated in Zucker fatty fatty (fa/fa) rats. In these animals with inherited leptin resistance, surgical resection of intra-abdominal fat depots reverses both conditions.33
Cytokines, adipokines, and steatohepatitis
As mentioned previously, similarities in the histopathology of alcohol induced steatohepatitis and obesity related NASH suggest that common mechanisms may mediate both diseases. In non-obese experimental animals in which chronic ingestion of alcohol containing diets was used to induce steatohepatitis, various treatments that inhibit TNF-α activity prevent alcohol induced steatohepatitis (reviewed by Tsukamoto and Lu34). Work by Sasaki and Wands35 and Mohr and colleagues36 has also suggested that chronic consumption of ethanol causes insulin resistance in rats and mice. Given evidence that the cellular mechanisms for insulin resistance also activate TNF-α production,16 it is not so surprising that insulin sensitising drugs that inhibit TNF-α37,38 protect mice from alcohol induced steatohepatitis.39 Recently, in a mouse model of NASH (for example, leptin deficient ob/ob mice), we showed that anti-TNF-α antibodies improve hepatic insulin sensitivity and NASH.40 Xu et al reported that non-obese ethanol fed mice and obese ob/ob mice both exhibit increased TNF-α and reduced adiponectin levels. Injections of recombinant adiponectin inhibited TNF-α, improved insulin sensitivity, and reversed steatohepatitis in lean (leptin sufficient) ethanol fed mice, as well as in obese mice with genetic leptin deficiency.41
Obese humans almost always have high serum levels of leptin.10 Therefore, it has been argued that results from studies of leptin deficient ob/ob mice may have little relevance to the pathogenesis of insulin resistance and NASH in obese humans.3,42 While there is no question that leptin levels in ob/ob mice and obese humans differ dramatically, both ob/ob mice and obese humans with the dysmetabolic syndrome have low levels of adiponectin and relatively high levels of TNF-α.10,41 In humans, various treatments that improve the dysmetabolic syndrome (for example, diet and exercise, thiazolidinediones) have been shown to increase adiponectin levels and reduce TNF-α.38,43 Therefore, it is becoming apparent that similar factors (that is, TNF-α and adiponectin) mediate NASH pathogenesis when leptin levels are increased and when leptin levels are reduced. Given this insight, it will be interesting to determine if supplementing adiponectin directly improves human insulin resistance and NASH.
NASH, FIBROGENIC FACTORS, AND CIRRHOSIS
In most liver diseases, including NASH, liver related morbidity and mortality are greatest in the subpopulation that progresses to cirrhosis.44,45 Because the epidemiology of fatty liver diseases in humans demonstrates that cirrhosis is more likely to occur in those with NASH than in those with simple steatosis,46 it has been suggested that the severity of chronic hepatic necroinflammation dictates the ultimate outcome of NASH in humans.3 Interestingly, this does not appear to be the case in rodents. Many genetically altered mice with severe steatohepatitis (for example, MAT-1α null mice, PPARα null mice) do not develop cirrhosis47,48 while cirrhosis is common in other strains (for example, microsomal triglyceride transferase deficient mice) that have significant steatosis but relatively trivial steatohepatitis (reviewed by Koteish and Diehl49). Studies of ob/ob mice have identified two obesity related factors that regulate hepatic fibrosis.
Direct comparison of ob/ob mice with steatohepatitis and wild-type mice with steatohepatitis induced by feeding antioxidant depleted methionine choline deficient (MCD) diets, demonstrates that hepatic oxidant stress and necroinflammation are comparable in mice with and without genetic leptin deficiency.50 However, leptin deficient mice develop significantly less hepatic fibrosis than wild-type mice, even when challenged by hepatotoxins, such as thioacetamide, or infections, such as schistosomiasis.51–55 Leptin replacement therapy normalises the hepatic fibrogenic response of ob/ob mice, demonstrating unequivocally that leptin is a critical regulator of liver fibrosis.55 However, the mechanisms by which leptin promotes hepatic fibrosis are poorly understood. Direct effects of leptin on hepatic stellate cells have been demonstrated by several groups.56,57 Although the particular type of leptin receptor that is involved remains controversial, there appears to be consensus that leptin induces PI3 kinase, promotes the growth of cultured stellate cells, and upregulates their collagen gene expression.58,59
Our group has suggested that leptin may also regulate hepatic fibrosis indirectly by modulating the production of cytokines and neurotransmitters. As mentioned previously, leptin deficient mice are relatively resistant to schistosoma induced hepatic fibrosis.54 In wild-type mice, the balance of Th-1 (proinflammatory) and Th-2 (anti-inflammatory, profibrogenic) cytokines regulates this process. Schistosoma infected mice with targeted disruption of the genes for both IL-4 and IL-10 do not develop liver fibrosis despite having a severe hepatic necroinflammatory response to infection. In contrast, schistosoma infected mice with targeted disruption of both IL-4 and IL-12 develop severe hepatic fibrosis despite having only trivial hepatitis.60 Leptin deficient ob/ob mice have reduced hepatic production of both IL-4 and IL-10, similar to leptin sufficient mice that are protected from schistosoma induced hepatic fibrosis. We showed that treating ob/ob mice with leptin (which normalises their fibrogenic response to liver injury) also increases their production of Th-2 (profibrogenic) cytokines, including IL-10.61
Natural killer T (NKT) cells
Components of the innate immune system, particularly NKT cells, play a key role in balancing the types of cytokines that are produced in the liver.62 We found that with age, the livers of leptin deficient ob/ob mice become selectively depleted of NKT cells due to increased rates of hepatic NKT cell apoptosis.63 Treatment with leptin increases hepatic NKT cell populations in ob/ob mice, suggesting that leptin directly or indirectly regulates NKT cell viability.61 Consistent with this concept, we showed that leptin increases IL-15, a cytokine that is known to expand NK T cell populations in the liver. Treating ob/ob mice with IL-15 dramatically increases their numbers of hepatic NKT cells despite persistent leptin deficiency. However, the effects of IL-15 are not restricted to NKT cells (IL-15 also dramatically expands NK cell populations). Moreover, IL-15 only slightly reduces NKT cell apoptosis, suggesting that other factors may play a more important role than IL-15 deficiency in mediating the reductions in hepatic NKT cell populations that occur during leptin deficiency.
Recent studies in our laboratory suggest that the neurotransmitter noradrenaline is likely to be a key regulator of hepatic NKT cell viability (unpublished data, see below). Leptin induces the production of noradrenaline. Thus leptin deficient ob/ob mice have reduced levels of noradrenaline.64 Recently, noradrenaline deficiency has been implicated in several of the peripheral consequences of leptin deficiency.65 In this regard, it is interesting that NKT cells express adrenoceptors66 because changes in noradrenaline might influence these cells. We have explored this possibility by studying both leptin sufficient and leptin deficient mice.
Our preliminary studies suggest that wild type mice with targeted disruption of the gene that encodes dopamine beta hydroxylase (Dbh, the enzyme catalyses the synthesis of noradrenaline from dopamine) have reduced hepatic NKT cell populations. Noradrenaline deficiency underlies depletion of hepatic NKT cell populations in Dbh null mice because treatment with adrenergic agonists restores their hepatic NKT cell numbers. This finding suggested to us that noradrenaline deficiency may also contribute to the decreased hepatic NKT cell populations in ob/ob mice. Therefore, we treated ob/ob mice with noradrenaline. This significantly reduced apoptosis of hepatic NKT cells and restored liver NKT cell populations to normal levels. Moreover, noradrenaline induced reconstitution of liver NKT cell populations terminated the overproduction of Th-1 cytokines (for example, TNF-α and interferon γ) by other types of cytokine producing cells, re-establishing balanced hepatic production of Th-1 and Th-2 cytokines despite persistent leptin deficiency (unpublished data). Therefore, both leptin (which increases noradrenaline) and noradrenaline itself enhance the activity of Th-2 cytokines. Th-2 cytokines are necessary to antagonise the activity of proinflammatory cytokines, such as TNF-α. However, as demonstrated by studies of schistosoma infected mice with targeted disruption of Th-2 cytokine genes, Th-2 cytokine activity is also necessary for hepatic fibrosis to develop during liver injury.
Noradrenaline, hepatic fibrosis, and leptin deficiency
Given this, we wondered if enhancing adrenergic activity in ob/ob mice might permit these animals to develop hepatic fibrosis despite ongoing leptin deficiency. To test this possibility, we gave ob/ob mice (which have mild chronic steatohepatitis) continuous infusions of noradrenaline for 2–4 weeks and evaluated the effects on hepatic stellate cells, transforming growth factor β (TGF-β), a key profibrogenic cytokine, collagen gene expression, and hepatic fibrosis.67 Noradrenaline treatment increased the numbers of activated stellate cells, induced TGF-β mRNA, upregulated collagen gene expression, and led to the pericellular and perisinusoidal accumulation of fibrous tissue in ob/ob mice. Enhancement in hepatic fibrogenesis occurred despite noradrenaline associated reductions in proinflammatory cytokine production by liver mononuclear cells and accompanying decreases in serum alanine aminotransferase levels. The mechanisms by which noradrenaline promotes hepatic fibrosis are likely to be complex. In addition to its effects on hepatic cytokine production, adrenergic activity is necessary for leptin to activate cultured stellate cells because prazosin, an alpha adrenergic antagonist, partially blocks leptin mediated increases in the growth of cultured stellate cells.67
The pathogenesis of NASH is being unravelled by studies of animal models and humans with this disorder. The necroinflammatory component of NASH appears to be modulated by interactions among various factors (for example, cytokines, hormones, neurotransmitters) that regulate the biological activity of TNF-α and other proinflammatory (Th-1) cytokines. Hepatic necroinflammation is necessary, but not sufficient, for progression to cirrhosis. Factors such as leptin and certain leptin inducible factors (for example, noradrenaline), that regulate the activity of profibrogenic cytokines, such as IL-10 and TGF-β, dictate the extent of fibrosis that occurs during liver injury. A better understanding of how these and other soluble and cell associated factors regulate the phenotypes of different types of liver cells should help us to develop rationale treatments for NASH and other disorders in the dysmetabolic syndrome.
This work was supported by grants RO1DK053792 and T32 DK07632 from the National Institutes of Health, USA.
Conflict of interest: None declared.